Last reviewed · How we verify
Standard Chemotherapy
Standard chemotherapy works by damaging cancer cell DNA or disrupting cell division, killing rapidly dividing cells.
Standard chemotherapy works by damaging cancer cell DNA or disrupting cell division, killing rapidly dividing cells. Used for Various solid tumors and hematologic malignancies (specific regimen and indication dependent on institutional protocol).
At a glance
| Generic name | Standard Chemotherapy |
|---|---|
| Also known as | Capecitabine, Docetaxel, Nab paclitaxel, Paclitaxel, AC-P |
| Sponsor | Oslo University Hospital |
| Drug class | Chemotherapy (multiple classes) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Standard chemotherapy encompasses multiple drug classes (alkylating agents, antimetabolites, topoisomerase inhibitors, microtubule disruptors) that act through different mechanisms including DNA cross-linking, nucleotide synthesis inhibition, or mitotic arrest. These drugs preferentially target rapidly dividing cancer cells but also affect normal dividing cells, leading to their characteristic toxicity profile.
Approved indications
- Various solid tumors and hematologic malignancies (specific regimen and indication dependent on institutional protocol)
Common side effects
- Myelosuppression (neutropenia, anemia, thrombocytopenia)
- Nausea and vomiting
- Mucositis
- Alopecia
- Diarrhea
- Fatigue
- Infection (due to immunosuppression)
- Cardiotoxicity (agent-dependent)
- Secondary malignancy (long-term)
Key clinical trials
- A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC) (PHASE2)
- Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) (PHASE2, PHASE3)
- BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia (PHASE2)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma (PHASE3)
- Durability of Three Monthly Loading Doses With Faricimab in Treatment-naïve Neovascular Age-related Macular Degeneration
- Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC) (PHASE2, PHASE3)
- A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Standard Chemotherapy CI brief — competitive landscape report
- Standard Chemotherapy updates RSS · CI watch RSS
- Oslo University Hospital portfolio CI